Literature DB >> 8368640

Performance of an asthma quality of life questionnaire in an outpatient setting.

B H Rowe1, A D Oxman.   

Abstract

The objectives of this study were to assess the validity, reliability, and responsiveness of a disease-specific quality of life questionnaire (AQLQ) in asthma patients presenting for assessment and treatment in an emergency department (ED). Fifty-two patients 18 to 64 yrs of age were surveyed in three EDs. Admitted and discharged patients with stable and unstable asthma were included. Patients were interviewed prior to discharge from the ED. They completed a self-report asthma questionnaire, the self-administered Sickness Impact Profile (SIP) and AQLQ, a global assessment of asthma severity, a symptom questionnaire, and pulmonary function testing. Forty-three (83%) patients were available for follow-up at 7 to 10 days, and they completed a similar series of tests. Moderate correlations were found between total SIP and AQLQ measurements (r = 0.49; p < 0.001). Correlations were high between physical domain scores of the SIP and AQLQ symptoms (r = 0.58; p < 0.0001) and activity limitations (r = 0.50; p < 0.0001). Low correlations were found between pulmonary function results and AQLQ domains, except activity limitations (r = 0.44; p < 0.001). High correlations were found between symptoms or global assessments and AQLQ (r > 0.6; p < 0.0001). The instrument is highly responsive to small changes in patient status and outperforms pulmonary function tests and symptom scores in this setting. Test-retest reliability in patients who were stable was substantial (intraclass correlation coefficients > 0.9) on all aspects of the AQLQ.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8368640     DOI: 10.1164/ajrccm/148.3.675

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  22 in total

1.  Asthma outcome measures.

Authors:  K D Watkins
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

2.  Internal consistency, reproducibility, responsiveness, and construct validity of the Chinese (HK) version of the asthma quality of life questionnaire.

Authors:  M Chan-Yeung; B Law; S Y Sheung; C L Lam
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 3.  Quality-of-life considerations in the treatment of asthma.

Authors:  E F Juniper
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

4.  An 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S).

Authors:  Eirini Grammatopoulou; Emmanouil Skordilis; Dimitra Koutsouki; George Baltopoulos
Journal:  Qual Life Res       Date:  2007-12-14       Impact factor: 4.147

5.  Impact of the global on patient perceivable change in an asthma specific QOL questionnaire.

Authors:  B L Barber; N C Santanello; R S Epstein
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

6.  Measuring quality of life in children with asthma.

Authors:  E F Juniper; G H Guyatt; D H Feeny; P J Ferrie; L E Griffith; M Townsend
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

7.  Knowledge, self-management, compliance and quality of life in asthma: a cross-sectional study of the French version of the Asthma Quality of Life Questionnaire.

Authors:  C Leroyer; T Lebrun; A Proust; X Lenne; E Lucas; G Rio; J D Dewitte; J Clavier
Journal:  Qual Life Res       Date:  1998-04       Impact factor: 4.147

8.  Can pharmacists influence the health-related quality of life of patients with asthma?: The New Zealand Pharmaceutical Care experience.

Authors:  N Kheir; L Emmerton; J Shaw
Journal:  J Sci Res Med Sci       Date:  2001-10

9.  Heart Rate Variability Biofeedback Does Not Substitute for Asthma Steroid Controller Medication.

Authors:  Paul M Lehrer; Charles G Irvin; Shou-En Lu; Anthony Scardella; Beatrix Roehmheld-Hamm; Milisyaris Aviles-Velez; Jessica Graves; Evgeny G Vaschillo; Bronya Vaschillo; Flavia Hoyte; Harold Nelson; Frederick S Wamboldt
Journal:  Appl Psychophysiol Biofeedback       Date:  2018-03

Review 10.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.